Clinical Trial Update: UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects [Phase 3]

View source ↗

Summary

This document reports the completion of the Phase 3 UNITY 1 trial evaluating a fixed-dose combination of daclatasvir, asunaprevir, and BMS-791325 for 12 weeks i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Asunaprevir (asunaprevir)
• BMS-791325
• Daclatasvir (daclatasvir)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C | Phase 3 | Status: COMPLETED